Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

1.

Designing of dual inhibitors for GSK-3β and CDK5: Virtual screening and in vitro biological activities study.

Xie H, Wen H, Zhang D, Liu L, Liu B, Liu Q, Jin Q, Ke K, Hu M, Chen X.

Oncotarget. 2017 Mar 14;8(11):18118-18128. doi: 10.18632/oncotarget.15085.

2.

Multi-step virtual screening to develop selective DYRK1A inhibitors.

Koyama T, Yamaotsu N, Nakagome I, Ozawa SI, Yoshida T, Hayakawa D, Hirono S.

J Mol Graph Model. 2017 Mar;72:229-239. doi: 10.1016/j.jmgm.2017.01.014. Epub 2017 Jan 15.

PMID:
28129593
3.

Binding mechanism of CDK5 with roscovitine derivatives based on molecular dynamics simulations and MM/PBSA methods.

Dong K, Wang X, Yang X, Zhu X.

J Mol Graph Model. 2016 Jul;68:57-67. doi: 10.1016/j.jmgm.2016.06.007. Epub 2016 Jun 16.

PMID:
27371933
4.

Novel optimization of valmerins (tetrahydropyrido[1,2-a]isoindolones) as potent dual CDK5/GSK3 inhibitors.

Ouach A, Boulahjar R, Vala C, Bourg S, Bonnet P, Guguen-Guillouzo C, Ravache M, Le Guevel R, Lozach O, Lazar S, Troin Y, Meijer L, Ruchaud S, Akssira M, Guillaumet G, Routier S.

Eur J Med Chem. 2016 Jun 10;115:311-25. doi: 10.1016/j.ejmech.2016.02.072. Epub 2016 Mar 2.

PMID:
27019296
5.

An evaluation of indirubin analogues as phosphorylase kinase inhibitors.

Begum J, Skamnaki VT, Moffatt C, Bischler N, Sarrou J, Skaltsounis AL, Leonidas DD, Oikonomakos NG, Hayes JM.

J Mol Graph Model. 2015 Sep;61:231-42. doi: 10.1016/j.jmgm.2015.07.010. Epub 2015 Aug 3.

PMID:
26364215
6.

Characterization of a Pyrazolo[4,3-d]pyrimidine Inhibitor of Cyclin-Dependent Kinases 2 and 5 and Aurora A With Pro-Apoptotic and Anti-Angiogenic Activity In Vitro.

Řezníčková E, Weitensteiner S, Havlíček L, Jorda R, Gucký T, Berka K, Bazgier V, Zahler S, Kryštof V, Strnad M.

Chem Biol Drug Des. 2015 Dec;86(6):1528-40. doi: 10.1111/cbdd.12618. Epub 2015 Sep 16.

PMID:
26198005
7.

Advances in tetrahydropyrido[1,2-a]isoindolone (valmerins) series: Potent glycogen synthase kinase 3 and cyclin dependent kinase 5 inhibitors.

Boulahjar R, Ouach A, Bourg S, Bonnet P, Lozach O, Meijer L, Guguen-Guillouzo C, Le Guevel R, Lazar S, Akssira M, Troin Y, Guillaumet G, Routier S.

Eur J Med Chem. 2015 Aug 28;101:274-87. doi: 10.1016/j.ejmech.2015.06.046. Epub 2015 Jun 27.

8.

Molecular Recognition of PPARγ by Kinase Cdk5/p25: Insights from a Combination of Protein-Protein Docking and Adaptive Biasing Force Simulations.

Mottin M, Souza PC, Skaf MS.

J Phys Chem B. 2015 Jul 2;119(26):8330-9. doi: 10.1021/acs.jpcb.5b04269. Epub 2015 Jun 19.

PMID:
26047365
9.

Tamoxifen inhibits CDK5 kinase activity by interacting with p35/p25 and modulates the pattern of tau phosphorylation.

Corbel C, Zhang B, Le Parc A, Baratte B, Colas P, Couturier C, Kosik KS, Landrieu I, Le Tilly V, Bach S.

Chem Biol. 2015 Apr 23;22(4):472-482. doi: 10.1016/j.chembiol.2015.03.009. Epub 2015 Apr 9.

10.

Discovery of thienoquinolone derivatives as selective and ATP non-competitive CDK5/p25 inhibitors by structure-based virtual screening.

Chatterjee A, Cutler SJ, Doerksen RJ, Khan IA, Williamson JS.

Bioorg Med Chem. 2014 Nov 15;22(22):6409-21. doi: 10.1016/j.bmc.2014.09.043. Epub 2014 Sep 28.

11.

CDK5 activator protein p25 preferentially binds and activates GSK3β.

Chow HM, Guo D, Zhou JC, Zhang GY, Li HF, Herrup K, Zhang J.

Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):E4887-95. doi: 10.1073/pnas.1402627111. Epub 2014 Oct 20. Erratum in: Proc Natl Acad Sci U S A. 2015 Jun 23;112(25):E3313.

12.

L312, a novel PPARγ ligand with potent anti-diabetic activity by selective regulation.

Xie X, Zhou X, Chen W, Long L, Li W, Yang X, Li S, Wang L.

Biochim Biophys Acta. 2015 Jan;1850(1):62-72. doi: 10.1016/j.bbagen.2014.09.027. Epub 2014 Oct 12.

PMID:
25305559
13.

Synthesis of new pyridazino[4,5-b]indol-4-ones and pyridazin-3(2H)-one analogs as DYRK1A inhibitors.

Bruel A, Bénéteau R, Chabanne M, Lozach O, Le Guevel R, Ravache M, Bénédetti H, Meijer L, Logé C, Robert JM.

Bioorg Med Chem Lett. 2014 Nov 1;24(21):5037-40. doi: 10.1016/j.bmcl.2014.09.017. Epub 2014 Sep 16.

PMID:
25248682
14.

Structural basis of valmerins as dual inhibitors of GSK3β/CDK5.

Li X, Wang X, Tian Z, Zhao H, Liang D, Li W, Qiu Y, Lu S.

J Mol Model. 2014 Sep;20(9):2407. doi: 10.1007/s00894-014-2407-1. Epub 2014 Aug 21.

PMID:
25142337
15.

A novel non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity.

Choi SS, Kim ES, Koh M, Lee SJ, Lim D, Yang YR, Jang HJ, Seo KA, Min SH, Lee IH, Park SB, Suh PG, Choi JH.

J Biol Chem. 2014 Sep 19;289(38):26618-29. doi: 10.1074/jbc.M114.566794. Epub 2014 Aug 6.

16.

Synthesis and optimization of an original V-shaped collection of 4-7-disubstituted pyrido[3,2-d]pyrimidines as CDK5 and DYRK1A inhibitors.

Dehbi O, Tikad A, Bourg S, Bonnet P, Lozach O, Meijer L, Aadil M, Akssira M, Guillaumet G, Routier S.

Eur J Med Chem. 2014 Jun 10;80:352-63. doi: 10.1016/j.ejmech.2014.04.055. Epub 2014 Apr 22.

PMID:
24793883
17.

Molecular basis of differential selectivity of cyclobutyl-substituted imidazole inhibitors against CDKs: insights for rational drug design.

Rath SL, Senapati S.

PLoS One. 2013 Sep 13;8(9):e73836. doi: 10.1371/journal.pone.0073836. eCollection 2013.

18.

Potential neuroprotective flavonoid-based inhibitors of CDK5/p25 from Rhus parviflora.

Shrestha S, Natarajan S, Park JH, Lee DY, Cho JG, Kim GS, Jeon YJ, Yeon SW, Yang DC, Baek NI.

Bioorg Med Chem Lett. 2013 Sep 15;23(18):5150-4. doi: 10.1016/j.bmcl.2013.07.020. Epub 2013 Jul 19.

PMID:
23927974
19.

Molecular dynamic simulations give insight into the mechanism of binding between 2-aminothiazole inhibitors and CDK5.

Wang W, Cao X, Zhu X, Gu Y.

J Mol Model. 2013 Jun;19(6):2635-45. doi: 10.1007/s00894-013-1815-y. Epub 2013 Mar 23.

PMID:
23525963
20.

Design, synthesis, and molecular modelling of pyridazinone and phthalazinone derivatives as protein kinases inhibitors.

Elagawany M, Ibrahim MA, Ali Ahmed HE, El-Etrawy ASh, Ghiaty A, Abdel-Samii ZK, El-Feky SA, Bajorath J.

Bioorg Med Chem Lett. 2013 Apr 1;23(7):2007-13. doi: 10.1016/j.bmcl.2013.02.027. Epub 2013 Feb 13.

PMID:
23453843

Supplemental Content

Loading ...
Support Center